美罗华治疗难治性系统性红斑狼疮的初步临床观察

摘要

目的：探讨美罗华治疗难治性系统性红斑狼疮的初步临床疗效及其安全性。方法选用我院收治的经传统治疗方法未能根治或缓解的难治性系统性红斑狼疮患者5例，对其采用美罗华（抗CD20单抗，即利妥昔单抗）治疗方法，观察分析其临床疗效及术后不良反应几率。结果3例患者经接受美罗华治疗后，临床疗效较为显著，B细胞在清除过程中患者无机体不适情况，治疗约2周后关节酸痛、肌肉疼痛等症状有明显缓解。随访3～15个月，3例患者的病情均有持续缓解。结论美罗华（抗CD20单抗）治疗难治性系统性红斑狼疮，临床疗效较为显著，能够明显缓解患者痛苦，帮助患者提高自身功能，值得在临床上进一步推广和应用。%Objective To investigate the preliminary clinical efficacy and safety ofrituximab in the treatment of refractory systemic lupus erythematosus. Methods Selected in our hospital the traditional treatment methods after failed to effect a radical cure or remission in patients with refractorysystemic lupus erythematosus in 5 cases,based on the Mei Luohua (anti CD20 monoclonal antibody,namely rituximab) treatment,observation of adverse reaction and analyse its clinical efficacy and postoperative risk.Results 3 patients accepted after rituximab therapy,remarkable clinical curative effect,B cels in the removal process of patients without body discomfort,about 2 weeks after the treatment of joint pain,muscle pain and other symptoms have obvious relief. Folowed up for 3~15 months,3 patientshad sustained remission of ilness.Conclusion Mei Luohua (anti CD20 antibody) in treatment of refractory systemic lupus erythematosus,more significant clinical effect,can reduce the pain of patients,help to improve their function of patients,is worthy of further promotion and application in clinical practice.